Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical
Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.
![Zydus Lifesciences inks licensing pact with Daewoong Pharmaceutical](https://cdn.zeebiz.com/sites/default/files/2023/12/11/272187-zydus.jpg?im=FitAndFill=(1200,900))
Zydus Lifesciences Ltd on Monday announced a licensing pact with South Korea's Daewoong Pharmaceutical Co Ltd to co-develop and commercialise a generic version of Leuprolide Acetate for depot suspension used to treat advanced prostatic cancer, endometriosis and uterine leiomyomata (fibroids).
Zydus Worldwide DMCC, a wholly-owned subsidiary, and Daewoong Pharmaceutical Co Ltd have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for depot suspension in six dosage strengths for the US market, Zydus Lifesciences said in a regulatory filing.
Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialisation in the US market, and Daewoong will be responsible for the pre-clinical studies, production and supply of the product, it added.
"Daewoong, utilising its proprietary technology, will produce Leuprolide Acetate for depot suspension in its manufacturing facilities located in Osong, South Korea," the filing said.
The exclusive agreement also includes development, regulatory and commercialisation milestone payments based on the successful outcome.
Additionally, this agreement also includes a profit share on future sales between the two companies, Zydus said without elaborating on financial details.
Commenting on the agreement, Zydus Lifesciences Managing Director Sharvil Patel said, "This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot, empowering patients with access to a critical therapy. This is yet another step to strengthen Zydus' complex injectable portfolio." Daewoong Pharmaceutical CEO Sengho Jeon said, "Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company in manufacturing the generic version of this complex, long-acting injectable Lupron Depot product." Leuprolide Acetate for depot suspension is a long-acting injectable product in a kit with a prefilled dual-chamber syringe, used for the treatment of advanced prostatic cancer, endometriosis, and uterine leiomyomata (fibroids), depending on its dosage regime, Zydus said.
Leuprolide Acetate for depot suspension had annual sales of approximately USD 671 million in the US with a growth rate of 10 per cent, the company said, citing IQVIA MAT October 2023 data.
Catch latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
![https://www.zeebiz.com/markets/stocks/photo-gallery-this-tata-group-stock-turned-every-rs-10000-of-investment-into-rs-11300-in-just-a-week-investors-richer-by-42722-crore-rupees-any-guesses-share-market-news-304023](https://cdn.zeebiz.com/sites/default/files/styles/zeebiz_700x394/public/2024/07/26/307143-tradingpexels.jpg?itok=rw4R7EfH)
A Tata group stock just turned every Rs 10,000 of investment into Rs 11,300 in just a week, investors richer by Rs 42,722 crore; any guesses?
![https://www.zeebiz.com/markets/stocks/photo-gallery-large-cap-midcap-stocks-shares-to-buy-for-long-term-check-out-targets-nifty-sensex-303617](https://cdn.zeebiz.com/sites/default/files/styles/zeebiz_700x394/public/2024/07/25/306716-stockks.jpg?itok=KJTrFUIK)
Stocks to buy for long term: Analysts suggest buying these 5 largecap, 4 midcap scrips; check out targets
![https://www.zeebiz.com/personal-finance/photo-gallery-nps-retirement-planning-budget-2024-nirmala-sitharaman-announcement-how-nps-rulebook-change-can-increase-corpus-income-and-monthly-pension-by-40-compound-return-303984](https://cdn.zeebiz.com/sites/default/files/styles/zeebiz_700x394/public/2024/07/26/307102-indian-currency-pixabay-take.jpg?itok=kN21EW-9)
How your NPS retirement corpus and monthly pension can jump by 40% after this rule change; get details
![https://www.zeebiz.com/personal-finance/photo-gallery-senior-citizen-savings-scheme-scss-2024-interest-rate-calculator-post-office-how-to-get-inr-rs-50000-interest-retirement-planning-guaranteed-return-maturity-amount-small-savings-303930](https://cdn.zeebiz.com/sites/default/files/styles/zeebiz_700x394/public/2024/07/26/307042-fd-interest-file.jpg?itok=45ZbBRWM)
How much investment do you need in this senior citizen scheme to get Rs 50,000 quarterly interest? Know here
11:55 AM IST